DBP International: The clinical protocol for the SI-053 phase I trial is finalized
Double Bond Pharmaceutical International AB (publ) (“DBP”) takes a step further towards the start of the phase 1 clinical trial of it’s front-line product SI-053 in patients with glioblastoma - the clinical protocol for the coming trial is now finalized.
The clinical protocol is an important document that forms the basis for applying for approval to authorities. It must, among other things, contain trial objectives and endpoints, overview that summarizes previous research results in the research area, trial description with presentation of design, treatment regimens including doses and